| HOME >> BIOLOGY >> TECHNOLOGY |
.5 343.3 +17
Other SG&A costs 329.2 252.9 +30
_______ _______ _______
1,041.4 829.4 +26
Depreciation, amortisation and impairment 339.7 390.5 -13
charges(1)
_______ _______ _______
Total SG&A costs 1,381.1 1,219.9 +13
_______ _______ ______
(1) Excludes (i) depreciation from manufacturing plants of US$5.0 million (2006: US$4.8 million) and amortisation of favourable supply contracts of US$1.2 million (2006: US$nil) which is included in cost of sales and (ii) other intangible assets impairment charges in respect of products under development of US$256.4 million (2006: US$nil) included in R&D.
Excluding depreciation, amortisation and impairment charges, SG&A costs increased by 26% to US$1,041.4 million (2006: US$829.4 million), and represented 48% of product sales (2006: 54%). The increase in SG&A expenses was expected, with additional expenditure required for:
- An increase in the ADHD sales force to promote VYVANSE;
- The cost of the new GI sales force in the US;
- The advertising, promotional and marketing spend to support the launches of VYVANSE, LIALDA and ELAPRASE; and
- A net charge of US$17.0 million in respect of legal settlements, being a charge of US$27.0 million for settlement of the TKT purported securities fraud class action shareholder suit relating to REPLAGAL, partially offset by a US$10.0 million release of existing legal provisions (1% of product sales).
The depreciation charge within SG&A for the year to December 31, 2007
was US$47.3 million (2006: US$36.0 million), which in 2007 included
property, plant and equipment write-downs of US$1.8 million (2006: US$0.5
mill
'/>"/>
| SOURCE Shire plc Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |